FDA lifts partial hold on OncoMed's ipafricept
This article was originally published in Scrip
For the second time in the past week, the FDA has lifted a partial hold on the Phase I studies of one of OncoMed Pharmaceuticals' drugs, this time ipafricept (FZD8-Fc, OMP-54F28), clearing the way for it to move forward.
You may also be interested in...
The California biotech's Phase II pancreatic cancer candidate demcizumab failed to show benefit versus placebo for progression-free or overall survival. Meanwhile, Bayer decided not to exercise its options on a pair of Wnt pathway candidates under a 2010 collaboration with OncoMed.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.